Novartis Plans $280 Million Manufacturing Plant in Denton
The eighth-largest pharmaceuticals company in the world, Swiss-based Novartis, is planning a $280 million manufacturing plant in Denton. This significant investment is expected to create new job opportunities and boost the local economy.
Location and Site Details
According to filings with the Denton City Council, Novartis is considering a 20-acre site at 2101 Shady Oaks Drive that has been nonoperational since 2009 and was last used by U.S. Radiopharmaceuticals. The property, which has 50,000 square feet of existing space, is currently owned by Kensington Title-Nevada, LLC.
Novartis has not officially announced the site and declined to comment when asked about the proposal. However, the company’s plans for the site are expected to be revealed in the coming weeks.
Manufacturing Plant Details
The plant will manufacture radioligand therapy (RLT) pharmaceuticals, a kind of targeted radiation therapy used for certain cancers. This type of therapy is a highly specialized and complex process that requires a high level of expertise and equipment.
In April, Novartis announced plans for $23 billion in investment over five years to expand its U.S. manufacturing footprint, including another new RLT facility in Florida, and expansions of existing facilities in Indiana, New Jersey and California.
Importance of Proximity to Treatment Centers
“Because each RLT dose is custom-made and time-sensitive, with a radioactive half-life measured in hours, proximity to treatment centers and transit hubs helps ensure patients receive their treatment when and where they need it,” reads the release announcing the California RLT facility.
This highlights the importance of having manufacturing facilities located close to treatment centers, as it enables the timely delivery of life-saving therapies to patients.
Incentives Package
On Tuesday, the Denton City Council will hear public comment on a city incentives package worth more than $3 million, including more than $2 million in a 10-year property tax abatement, a sales tax rebate for construction materials and job-based and remediation grants.
The project also has a pending “deal-closing” grant from the Texas Enterprise Fund of unspecified value and state property tax exemption worth about $5.9 million over 10 years.
Site Cleanup and Renovation
The first phase of the project will be removing hazardous materials from the site, according to a presentation prepared for the city. According to the Denton Record-Chronicle, the Shady Oaks site has been the subject of a property tax dispute between Kensington and U.S. Radiopharmaceuticals, and cleanup of low-level radioactive waste ceased in 2019.
The interiors of the existing buildings will be completely remodeled and upgraded for Novartis’ specialized manufacturing processes, and a tunnel with a boronated bunker will be retrofitted for secure containment and shielding of radioactive materials.
Job Creation and Economic Impact
The plant is planned to create at least 150 jobs with an average salary of more than $124,000, many in technical roles. This will not only provide employment opportunities for local residents but also contribute to the growth of the local economy.
Denton expects to see returns on its incentives after about three years, for a total of $4.8 million over 10 years. The city estimates the plant would generate an additional $1.9 million for the county, $5.2 million for the school district and $449,729 for the transit district in tax revenue.
Conclusion
In conclusion, the planned $280 million manufacturing plant in Denton is a significant investment that is expected to create new job opportunities, boost the local economy, and provide life-saving therapies to patients. The city’s incentives package and the company’s commitment to expanding its U.S. manufacturing footprint are testaments to the importance of this project.
Frequently Asked Questions
Q: What type of pharmaceuticals will the plant manufacture?
A: The plant will manufacture radioligand therapy (RLT) pharmaceuticals, a kind of targeted radiation therapy used for certain cancers.
Q: How many jobs will the plant create?
A: The plant is planned to create at least 150 jobs with an average salary of more than $124,000, many in technical roles.
Q: What is the total investment in the project?
A: The total investment in the project is $280 million.
Q: What is the expected return on investment for the city?
A: The city expects to see returns on its incentives after about three years, for a total of $4.8 million over 10 years.
